Antidepressants for youth depression: Cochrane review confirms they should not be the first port of call

Pharmaceutical medicine pills, tablets and capsules on mint background. Top view. Flat lay. Copy space. Medicine concepts. Minimalistic abstract concept. Neo mint color

Susannah Murphy summarises a new Cochrane review and network meta-analysis, which provides the best evidence to date about new generation antidepressants for depression in children and adolescents.

[read the full story...]

Antidepressants and psychotherapy for adolescent depression: can they be compared? #ActiveIngredientsMH

hendrik-kespohl-eD_YBIPNV3o-unsplash

Catherine Harmer summarises a recent network meta-analysis relating to her own Wellcome Trust funded research into antidepressants for young people with anxiety or depression.

[read the full story...]

Time to stop prescribing antidepressants to young people with depression?

photo-1456397807017-5a6b47d257f4

Andrew Shepherd considers the implications of a recent network meta-analysis of the efficacy and tolerability of antidepressants for children and adolescents with depression.

[read the full story...]

Antidepressants: benefits and harms in children and adults

344574172_eaccb04842_o

Samei Huda discusses the findings of a recent review into suicidality and aggression during antidepressant treatment. The systematic review and meta-analyses were based on clinical study reports and included some important adverse effects of antidepressants in children and young people.

[read the full story...]

CBT is more cost-effective than SSRI alone as treatment for panic disorder

shutterstock_32610631crop

In addition to its impact on quality of life, panic disorder can have a number of costly consequences such as lost productivity – particularly if also associated with agoraphobia. Cost-effectiveness is therefore an important consideration in choosing the optimal treatment for panic disorder, which might improve value via the cost side of the equation. A recent [read the full story…]

Cochrane review says there’s insufficient evidence to tell whether fluoxetine is better or worse than other treatments for depression

shutterstock_65894887

Depression is common in primary care and associated with a substantial personal, social and societal burden. There is considerable ongoing controversy regarding whether antidepressant pharmacotherapy works and, in particular, for whom. One widely-prescribed antidepressant is fluoxetine (Prozac), an antidepressant of the selective serotonin reuptake inhibitors (SSRI) class. Although a number of more recent antidepressants are [read the full story…]